We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV

By HospiMedica International staff writers
Posted on 30 Jun 2026

Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. More...

In England, about one in 20 people living with HIV are unaware of their status, underscoring persistent gaps in routine screening pathways. New findings now demonstrate how a large-scale emergency department opt-out testing initiative is detecting infections earlier and linking patients to care.

The UK National Health Service (NHS) Blood Borne Virus Opt-Out Testing Program is a first-of-its-kind large-scale initiative operating in hospital emergency departments (EDs). Adults attending EDs in 88 towns and cities with high HIV prevalence who are already having blood drawn are routinely tested for HIV, hepatitis B, and hepatitis C unless they opt out. Individuals with positive results are then offered specialist support and a treatment plan.

According to the latest NHS data, the program has identified 1,900 previously undiagnosed HIV cases since it launched in April 2022. An economic evaluation published in The Lancet HIV and led by the University of Bristol and the National Institute for Health and Care Research (NIHR) estimated that 802 diagnoses from the program’s initial phase could avert about 187 HIV-related deaths and 28 new infections over 20 years.

Research by the UK Health Security Agency (UKHSA) found that 93% of newly diagnosed individuals reached by the initiative had no record of a prior HIV test, indicating that the model is engaging people unlikely to be tested through other pathways.

The study concluded the approach offers good value for the NHS, citing a low per-test cost and the clinical benefits of earlier diagnosis and treatment initiation. The program forms part of national efforts to reduce HIV transmission, with NHS leaders continuing the rollout and three additional hospitals expected to begin ED testing by April 2027. The government’s HIV Action Plan 2025–2030 also sets out continued investment to sustain opt-out testing for HIV, hepatitis B, and hepatitis C in high-prevalence areas.

“At around £6 per HIV test, the program is good value for money for the NHS, and importantly has led to linkage to treatment to improve the health and lifespan of many people who were previously living with undiagnosed HIV,” said Dr. Josephine Walker, lead author at the University of Bristol and NIHR Health Protection Research Unit in Evaluation and Behavioural Science.

“Knowing your HIV status is as important as checking your blood pressure, and our pioneering NHS Blood Borne Virus Opt-Out Testing Program is helping hundreds of people get a diagnosis—often before they have any symptoms at all—which means they have access to life-saving treatment," said Professor Francesca Swords, national medical director for the NHS.

"NHS staff are committed to improving early detection of HIV and other blood-borne viruses, and improving awareness of these health conditions to reduce the chance of people unknowingly passing it on to others. The successful rollout of this initiative in hospital EDs is an excellent example of how the NHS is working to make every contact with patients matter by supporting people to stay well, access treatment, save lives and make the best use of its resources,” added Prof. Swords.

Related Links
University of Bristol 
NIHR


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hand-held Hemoglobin Analyzer
DiaSpect Tm
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image:The NCIBT team with the cath lab members celebrating the completion of the study. (Image Credit: UC Davis)

Dual-Imaging Catheter Completes Initial Human Evaluation of Coronary Plaque

Atherosclerosis involves plaque buildup in arterial walls that can narrow blood vessels and increase the risk of heart attack, stroke, and other serious cardiovascular conditions. In coronary arteries,... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.